Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis-Reference-Cited by-同舟云学术

Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis

Published:2021-09 Issue:9 Volume:24 Page:103078
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Asplund Högelin Klara,Ruffin Nicolas^ORCID,Pin Elisa,Månberg Anna,Hober Sophia^ORCID,Gafvelin Guro,Grönlund Hans,Nilsson Peter^ORCID,Khademi Mohsen,Olsson Tomas,Piehl Fredrik,Al Nimer Faiez

Funder

PCORI

Swedish Research Council

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference56 articles.

1. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies;Achiron;Ther. Adv. Neurol. Disord.,2021

2. High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris;Anna;Eur. J. Immunol.,2020

3. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis;Baker;EBioMedicine,2017

4. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases;Baker;Clin. Exp. Immunol.,2020

5. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study;Bar-Or;Neurology,2020

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study;Journal of Neurology, Neurosurgery & Psychiatry;2024-05-14

2. Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs;Clinical Immunology Communications;2023-12

3. Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models;Human Vaccines & Immunotherapeutics;2023-11-27

4. The impact of hybrid immunity on immune responses after SARS‐CoV‐2 vaccination in persons with multiple sclerosis treated with disease‐modifying therapies;European Journal of Neurology;2023-08-24

5. Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study;Frontiers in Immunology;2023-06-28